Kuros BiosciencesCSBTF 71 PS Ratio is 5.21 as of Jun. 27, 2026, which is 60% below its 10-year median of 12.93. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.72 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 71.52% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Kuros Biosciences's share price is $22.72.
Kuros Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $4.36. Hence, Kuros Biosciences's PS Ratio for today is 5.21.
Good Sign:
Kuros Biosciences Ltd stock PS Ratio (=5.24) is close to 2-year low of 5.24.
The historical rank and industry rank for Kuros Biosciences's PS Ratio or its related term are showing as below:
CSBTF'
s PS Ratio Range Over the Past 10 Years
Min: 1.81 Med: 12.93 Max: 173.46
Current: 4.61
During the past 13 years, Kuros Biosciences's highest PS Ratio was 173.46. The lowest was 1.81. And the median was 12.93.
CSBTF's PS Ratio is ranked worse than 71.52% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.86
vs CSBTF: 4.61
During the past 12 months, the average Revenue per Share Growth Rate of Kuros Biosciences was 54.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 88.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 81.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 21.20% per year.
During the past 13 years, Kuros Biosciences's highest 3-Year average Revenue per Share Growth Rate was 131.40% per year. The lowest was -78.40% per year. And the median was 1.70% per year.
Back to Basics: PS Ratio
Kuros Biosciences (OTCPK:CSBTF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Kuros Biosciences PS Ratio Related Terms
Kuros Biosciences PS Ratio Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Kuros Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Kuros Biosciences's Share Price of today is $22.72.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $4.36.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Kuros Biosciences (CSBTF) has a PS Ratio of 5.21 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kuros Biosciences and its competitors. This is 60% below median its historical median of 12.93. Over the past decade, Kuros Biosciences' PS Ratio has ranged from 1.81 to 173.46. According to the industry distribution chart, Kuros Biosciences ranks #575 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 71.5%.
Is Kuros Biosciences' PS Ratio too high?
Kuros Biosciences' current PS Ratio of 5.21 is 60% below median its 10-year median of 12.93. Over the past 10 years, this metric has ranged from a low of 1.81 to a high of 173.46. The Medical Devices & Instruments industry median PS Ratio is 2.86. Kuros Biosciences' value of 5.21 is 82.2% above this industry median. Based on the distribution chart, Kuros Biosciences ranks #575 out of 804 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #575 out of 804 companies for PS Ratio. This places Kuros Biosciences in the lower half of its industry. The industry median PS Ratio is 2.86. Kuros Biosciences' value of 5.21 is 82.2% above this benchmark. Historically, Kuros Biosciences' own PS Ratio has ranged from 1.81 to 173.46 over the past decade. While the company's 10-year median is 12.93 vs. the industry median of 2.86, Kuros Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.86, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current PS Ratio of 5.21 is 82.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current PS Ratio is 5.21, which is 60% below median its own 10-year median of 12.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.72, compared to a current price of $22.72 — trading 58.5% below its estimated fair value. The current PS Ratio is 5.21, which is 60% below median its 10-year median of 12.93 and 82.2% above the Medical Devices & Instruments industry median of 2.86. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current PS Ratio is 5.21 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 58.5% below its estimated GF Value™ of $54.72.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
PS Ratio: 5.21 (60% below median its 10-year median of 12.93)
GF Value™: $54.72 vs. price of $22.72 (58.5% below fair value)
Industry Position: 82.2% above the Medical Devices & Instruments median (#575 of 804)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
